Definitive Healthcare (NASDAQ:DH) Receives “Hold” Rating from Needham & Company LLC

Definitive Healthcare (NASDAQ:DH)‘s stock had its “hold” rating restated by analysts at Needham & Company LLC in a research note issued to investors on Thursday,Benzinga reports.

A number of other equities research analysts also recently weighed in on the company. Stephens initiated coverage on Definitive Healthcare in a research report on Friday, December 20th. They set an “equal weight” rating and a $5.00 target price on the stock. Barclays reiterated an “underweight” rating and issued a $4.00 price objective on shares of Definitive Healthcare in a research report on Monday. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Definitive Healthcare currently has an average rating of “Hold” and an average target price of $5.72.

Definitive Healthcare Price Performance

Shares of Definitive Healthcare stock opened at $3.98 on Thursday. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.49 and a quick ratio of 2.49. The company has a market cap of $459.78 million, a PE ratio of -1.28, a price-to-earnings-growth ratio of 3.14 and a beta of 1.41. The firm has a fifty day moving average price of $4.36 and a two-hundred day moving average price of $4.51. Definitive Healthcare has a fifty-two week low of $3.19 and a fifty-two week high of $10.62.

Insider Buying and Selling at Definitive Healthcare

In related news, insider William Moschella sold 45,000 shares of Definitive Healthcare stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $4.70, for a total value of $211,500.00. Following the completion of the transaction, the insider now directly owns 433,830 shares of the company’s stock, valued at $2,039,001. The trade was a 9.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 14.84% of the company’s stock.

Hedge Funds Weigh In On Definitive Healthcare

Institutional investors have recently modified their holdings of the stock. The Manufacturers Life Insurance Company grew its stake in shares of Definitive Healthcare by 17.0% during the second quarter. The Manufacturers Life Insurance Company now owns 22,896 shares of the company’s stock valued at $125,000 after purchasing an additional 3,332 shares during the last quarter. Glenmede Trust Co. NA lifted its holdings in Definitive Healthcare by 41.1% during the 3rd quarter. Glenmede Trust Co. NA now owns 18,423 shares of the company’s stock worth $82,000 after buying an additional 5,362 shares in the last quarter. Point72 DIFC Ltd boosted its position in Definitive Healthcare by 759.9% in the 3rd quarter. Point72 DIFC Ltd now owns 9,296 shares of the company’s stock valued at $42,000 after buying an additional 8,215 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Definitive Healthcare by 50.5% in the 2nd quarter. Renaissance Technologies LLC now owns 28,900 shares of the company’s stock valued at $158,000 after buying an additional 9,700 shares during the period. Finally, Intech Investment Management LLC bought a new stake in shares of Definitive Healthcare during the third quarter worth $55,000. 98.67% of the stock is owned by institutional investors.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.